<DOC>
	<DOCNO>NCT02795767</DOCNO>
	<brief_summary>This single-arm study enroll child ( less [ &lt; ] 12 year age ) adolescent ( 12 17 year age ) hemophilia A FVIII inhibitor currently receive treatment bypass agent . Participants receive weekly subcutaneous ( SC ) dose emicizumab designated period 52 week . All participant continue receive standard care/background treatment usual episodic bypassing agent therapy treat breakthrough bleeds need .</brief_summary>
	<brief_title>A Study Once-Weekly Emicizumab Children Adolescents With Hemophilia A Factor VIII ( FVIII ) Inhibitors ( HAVEN 2 )</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Children &lt; 12 year age , allowance participant 12 17 year age weigh &lt; 40 kilogram ( kg ) participant &lt; 2 year age protocoldefined interim data review criterion meet Diagnosis hemophilia A severity hightiter FVIII inhibitor ( , great equal [ &gt; /= ] 5 Bethesda unit [ BU ] ) Requirement treatment bypass agent Adequate hematologic , hepatic , renal function Inherited acquire bleed disorder hemophilia A Ongoing ( plan receive study ) immune tolerance induction ( ITI ) therapy prophylaxis treatment FVIII Previous ( past 12 month ) current treatment thromboembolic disease sign thromboembolic disease Other disease may increase risk bleed thrombosis Hypersensitivity monoclonal antibody component emicizumab injection Known human immunodeficiency virus ( HIV ) hepatitis B C Use systemic immunomodulators Planned surgery study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>